Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dr. Martens PLC Board/Management Information 2022

Jun 29, 2022

5055_mang_2022-06-29_e240fa99-4154-4559-bed7-ee335d7cab3e.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 6030Q

Dr. Martens PLC

29 June 2022

29 June 2022

Dr. Martens plc

Director Declaration

Dr. Martens plc (the Company) announces that it has been informed that Lynne Weedall will be stepping down from the Board of Treatt PLC with effect from 17 September 2022.

The Company also notes that Stagecoach Group PLC, of which Lynne is a non-executive director, has confirmed that the listing of its shares on the premium listing segment of the Official List and their admission to trading on the main market of the London Stock Exchange were each cancelled with effect from 8.00am on 28 June 2022.

This announcement is made by the Company pursuant to Listing Rule 9.6.14(1).

ENDS

Enquiries:

Paul Rolling, Assistant Company Secretary       +447584243562

About Dr. Martens plc:

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

The Company successfully listed on the main market of the London Stock Exchange in January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RDNQKLBLLQLXBBE